MedTrace Logo

Imagery Rescripting as Treatment for Depression

NCT05976945 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-05-06

No results posted yet for this study

Summary

The goal of this multiple baseline case series study is to test Imagery Rescripting in depression. The main question\[s\] it aims to answer are:

* does Imagery Rescripting lead to a reduction of depression and of believability of negative beliefs held by the participants?
* does Imagery Rescripting also leads to reductions in worrying and brooding?
* Participants will wait for 6-10 weeks (to assess time effects without treatment), followed by 5 weekly preparation sessions, 8-12 weekly Imagery Rescripting sessions, and 5 weeks post-treatment.
* Participants will rate the believability of 3-5 core dysfunctional beliefs related to their depression as well as 2 items assessing depression severity on a weekly basis. In addition, they will fill out more extensive questionnaires on depression, worry and brooding before each phase, as well as at 5 weeks post-treatment, and 6 and 12 months follow-up.

Conditions

Interventions

BEHAVIORAL

Imagery Rescripting

In Imagery Rescripting patients imagine a different sequence of events matching their needs better than what actually happened in traumatic and other adverse (childhood) experiences.

Sponsors & Collaborators

  • Academic Center for Trauma and Personality

    collaborator UNKNOWN

  • University of Amsterdam

    lead OTHER

Principal Investigators

  • Arnoud Arntz, PhD · University of Amsterdam

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-10
Primary Completion
2026-08-01
Completion
2027-08-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05976945 on ClinicalTrials.gov